Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement
Journal Articles International Journal of Cardiology Year : 2013

Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison

Abstract

Dual antiplatelet therapy with Aspirin and Clopidogrel has been considered as a cornerstone therapy after acute coronary syndrome (ACS) [1] before new P2Y12 blockers demonstrated their clinical benefit in large randomized controlled trials [2,3]. European guidelines [4] recommended the use of Prasugrel or Ticagrelor in ACS patients as first choice. Prasugrel is the more recent available thienopyridine drug, and Ticagrelor, a direct and reversible P2Y12 blocker, is preferred with a higher level of evidence than Clopidogrel (level B for both versus C).

Dates and versions

hal-02652055 , version 1 (29-05-2020)

Identifiers

Cite

Pierre Deharo, Clemence Bassez, Guillaume Bonnet, Mathieu Pankert, Jacques Quilici, et al.. Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. International Journal of Cardiology, 2013, 170 (2), pp.E21-E22. ⟨10.1016/j.ijcard.2013.10.043⟩. ⟨hal-02652055⟩
20 View
0 Download

Altmetric

Share

More